DepressionAMENDNCT07218055
Assessment of Music Experiences in Navigating Depression Part 2
A study testing Music therapy in people with Depression, run by Icahn School of Medicine at Mount Sinai at 1 site in United States.
Trial summary
This study is again looking at the use of music and music therapy experiences in navigating depression. The researchers will provide 11 sessions of music therapy and half will be followed by recitals at the Third Street School Music Settlement where the kids enrolled in our study will observe and interact with the… Read more about this study
- Who is it for?
- Ages 7 to 15 years
- Conditions the study is for
- Depression
- What is being tested?
- Music therapy
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteUnited States
- Study dates
- 8 Sep 2025to 4 Aug 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 7 to 15 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Must indicate depression -or symptoms thereof by parent in writing
- We are including children only in Amend II
Who cannot join
- none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mount Sinai Union Square
New York, New York, 10003
Joanne V Loewy, Doctorate, 212 420-3484, Joanne.Loewy@mountsinai.org
Shantelena Mouzon, 212 844-8387, Shantelena.Mouzon@mountsinai.org
About this study
Official title: Assessment of Music Experiences in Navigating Depression (AMEND)
This study is again looking at the use of music and music therapy experiences in navigating depression. The researchers will provide 11 sessions of music therapy and half will be followed by recitals at the Third Street School Music Settlement where the kids enrolled in our study will observe and interact with the performers and discuss and reflect on anxiety and performance and how sharing personal creativity affects them intra and interpersonally.
Read the detailed description
The researchers will provide hourly weekly music therapy sessions and then go to the Third Street Music School and work with their kids and our kids providing insights and feedback. The researchers will test their depression (CDI) and Resilience (Connor Davidson)
- Conditions
- Depression
- Being tested
- Music therapy
- Keywords
- Children's sadness, anxiety, fragility, music experiences in child assessment
- Medical subject headings
- Depression, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Music therapyOther
Also called Verbal procession concert activity
hourly weekly music therapy sessions
| Study group | Role | What they receive |
|---|---|---|
| Music | Experimental | Will receive assessment of music and 11 music therapy sessions as well as pretesting and f/u testing Receives: Other: Music therapy |
| Control | Sham comparator | Will receive assessment of music pre-testing and follow up post testing Receives: Other: Music therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Conor-Davidson Resilience Scale
The Conor-Davidson Resilience Scale 10-item (Conor \& Davidson, 2003, 2007) or CD-RISC10 is scale measuring the resilience of an individual. Each item is rated on a 5-point scale from 0 (not true at all) to 4 (True nearly all the time) with scoring from 0 to 40. The higher an individual scores, the greater their resilience. The lower an individual scores, the lower the individual's resilience.
Measured: end of 6 months
Secondary outcomes (1)
CDI2 or Children's Depression Inventory, Second Edition
The CDI2 is a self reported scale coming in two versions, CDI2 (28 items) and CDI2S (12 items). For this study, the CDI2S was chosen. Each item is rated on a 3-point scale from 0 to 2 with scoring from 0 to 24. 0 indicates no symptom, 1 indicates mild symptom, and 2 indicates definite symptom per item. The higher the total score, the stronger the indication for depression. Individuals who score from 0-12 indicate minimal to no depressive symptoms, individuals who score from 13-19 indicate mild depressive symptoms, and individuals who score 20 and above indicate moderate to severe depressive symptoms
Measured: end of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2025
- Study start8 Sep 2025
- Primary completion4 Aug 2026 (estimated)
- Study completion4 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DepressionStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Ransom assignment to intervention or control across 6 month period-11 sessions
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Collaborators
- Third Street Music School
- Responsible party
- Principal investigator, Joanne Loewy, Icahn School of Medicine at Mount Sinai
- Investigators
- Joanne V Loewy, D.A., LCAT, MT-BC, Study chair, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07218055
- Sponsor's protocol ID
- STUDY-22-01609-CR004
- Other IDs
- STUDY-22-01609-CR004
- Acronym
- AMEND
- Status last verified
- Oct 2025
- First submitted
- 15 Oct 2025
- Last updated
- 17 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).